C12N 2710/24171
Demonstrated in vivo effect
C12N2710/24171 (Demonstrated in vivo effect) appears on 49 US grants and 84 published applications in this corpus.
Search patents in C12N- Granted patents
- 49
- Published applications
- 84
- Assignees
- 52
- Inventors
- 159
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 2 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 1 |
| 2009 | 0 | 3 |
| 2010 | 0 | 2 |
| 2011 | 1 | 1 |
| 2012 | 0 | 1 |
| 2013 | 0 | 4 |
| 2014 | 3 | 2 |
| 2015 | 3 | 5 |
| 2016 | 2 | 8 |
| 2017 | 5 | 5 |
| 2018 | 3 | 5 |
| 2019 | 2 | 5 |
| 2020 | 3 | 4 |
| 2021 | 6 | 8 |
| 2022 | 4 | 6 |
| 2023 | 2 | 7 |
| 2024 | 0 | 6 |
| 2025 | 4 | 5 |
| 2026 | 6 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods comprising oncolytic viruses expressing CD19T and bispecific T cell engagers4 Aug 2026US 12,698,512 B2City of Hope
- Oncolytic vaccinia virus21 Jul 2026US 12,686,856 B2KM Biologics Co., Ltd.
- Oncolytic vaccinia virus26 May 2026US 12,637,663 B2KM Biologics Co., Ltd.
- Synthetic modified vaccinia Ankara (SMVA) based coronavirus vaccines24 Mar 2026US 12,584,146 B2City of Hope
- Immunotherapeutic vaccine and antibody combination therapy10 Feb 2026US 12,544,415 B2Transgene S. A.
- Recombinant chimeric antigen for poxvirus, subunit vaccine comprising same and use thereof6 Aug 2026US 2026/0226110 A1Beihang University
- Use of dr-18 and oncolytic vaccinia virus in preparation of anti-tumor drug4 Jun 2026US 2026/0151445 A1Guangzhou Virotech Pharmaceutical Co., Ltd.
- Recombinant virus expressing interleukin-1212 Mar 2026US 2026/0071233 A1AstraZeneca AB
- Synthetic modified vaccinia ankara (smva) based coronavirus vaccines9 Oct 2025US 2025/0313858 A1City of Hope
- Poxvirus-based vectors produced by natural or synthetic dna and uses thereof3 Jul 2025US 2025/0215456 A1City of Hope
Most cited
By later US patents
- Preparation and use of viral vectors for mixed envelope protein immunogenic composition against human immunodeficiency viruses38US 5,846,546 ASt. Jude Children?S Research Hospital · 1998
- Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF35US 6,093,700 AThomas Jefferson University · 2000
- Method of inducing an immune response using vaccinia virus recombinants27US 6,475,999 B1Thomas Jefferson University · 2002
- Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses20US 5,741,492 ASt. Jude Children?S Research Hospital · 1998
- Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors15US 10,548,930 B2Memorial Sloan Kettering Cancer Center · 2020